Clarivate Q4 revenue $617M, down 7%; pursues LS&H sale; FY26 FCF ~$400M

CLARIVATE PLC

2025-FY EPS reported -$0.30 revenue$2,455,200,000

Q4 net income $3.1M vs loss $191.8M; adjusted EPS $0.20 vs $0.21. Full-year adjusted EBITDA $1,001.8M.
Organic ACV grew 1.8% in FY2025; recurring revenue mix improved to 88% of total revenue.
Pursuing sale of Life Sciences & Healthcare; retained Morgan Stanley; proceeds to reduce leverage.
FY2026 outlook: Adj. EBITDA growth with ~200 bps margin expansion; FCF ~$400M at midpoint.
Returned $225M to shareholders via share repurchases in 2025 (56M shares).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.